Please login to the form below

Not currently logged in

Merck says osteoporosis drug clears phase II trial

Odanacatib on track for 2013 filing

A phase II trial of Merck & Co's osteoporosis drug candidate has yielded positive results, putting the programme on track for regulatory filings in 2013, says the company.

Odanacatib - currently leading a new class of osteoporosis drugs called cathepsin K inhibitors - has already shown efficacy in reducing fractures in a phase III trial and has been tipped to make sales of $3bn or more at peak.

The latest phase II data indicate that odanacatib significantly increased bone mineral density (BMD) over a two-year period in post-menopausal women with osteoporosis who previously had three or more years of treatment with alendronate, a long-standing drug for the disease which Merck sells as Fosamax.

Patients in the study were randomised to receive either odanacatib or placebo once a week on top of calcium and vitamin D supplements if needed.

At the end of the two-year treatment period, Merck's drug raised BMD by around 1 to 2 per cent - depending on the site tested - while the placebo group saw declines of around the same margin. For example, lumbar spine density increased over 2 per cent with odanacatib but decline by 0.3 per cent in the placebo group.

"We're excited about these results because understanding the effects of odanacatib in a population of post-menopausal women previously treated for osteoporosis is important to clinicians," said Albert Leung, executive director of clinical research at Merck Research Laboratories.

Critically, odanacatib has a favourable safety profile compared to older bisphosphonate-based medicines for osteoporosis like Fosamax, which are associated with gastrointestinal problems as well as rare cases in which bone tissue can start to decay.

Odanacatib is one of five drugs in development at Merck that it hopes will help it return to buoyant growth since losing patent protection on some of its blockbuster brands, notably $6bn-a-year asthma and allergy treatment Singulair (montelukast).

Others include first-in-class insomnia treatment suvorexant, neuromuscular reversal agent Bridion (sugammadex), HPV vaccine V503, and atherosclerosis medicine Tredaptive ER (nicotinic acid/laropiprant).

15th October 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Hamell is a full service behaviour change agency with a focus on delivering sustained change through a deep understanding of...

Latest intelligence

‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...
2015/16 Pharmaceutical Titles
Browse our latest interactive Pharmaceutical and Healthcare catalogue...